Literature DB >> 30892695

Influence of Multimorbidity on Burden and Appropriateness of Implantable Cardioverter-Defibrillator Therapies.

Alexandra M Hajduk1, Jerry H Gurwitz2, Grace Tabada3, Frederick A Masoudi4, David J Magid5,6, Robert T Greenlee7, Sue Hee Sung3, Andrea E Cassidy-Bushrow8, Taylor I Liu9, Kristi Reynolds10, David H Smith11, Frances Fiocchi12, Robert Goldberg2, Thomas M Gill1, Nigel Gupta13, Pamela N Peterson4,6, Claudio Schuger14, Humberto Vidaillet15, Stephen C Hammill16, Heather Allore1, Alan S Go3,17,18.   

Abstract

OBJECTIVE: To determine whether burden of multiple chronic conditions (MCCs) influences the risk of receiving inappropriate vs appropriate device therapies.
DESIGN: Retrospective cohort study.
SETTING: Seven US healthcare delivery systems. PARTICIPANTS: Adults with left ventricular systolic dysfunction receiving an implantable cardioverter-defibrillator (ICD) for primary prevention. MEASUREMENTS: Data on 24 comorbid conditions were captured from electronic health records and categorized into quartiles of comorbidity burden (0-3, 4-5, 6-7 and 8-16). Incidence of ICD therapies (shock and antitachycardia pacing [ATP] therapies), including appropriateness, was collected for 3 years after implantation. Outcomes included time to first ICD therapy, total ICD therapy burden, and risk of inappropriate vs appropriate ICD therapy.
RESULTS: Among 2235 patients (mean age = 69 ± 11 years, 75% men), the median number of comorbidities was 6 (interquartile range = 4-8), with 98% having at least two comorbidities. During a mean 2.2 years of follow-up, 18.3% of patients experienced at least one appropriate therapy and 9.9% experienced at least one inappropriate therapy. Higher comorbidity burden was associated with an increased risk of first inappropriate therapy (adjusted hazard ratio [HR] = 1.94 [95% confidence interval {CI} = 1.14-3.31] for 4-5 comorbidities; HR = 2.25 [95% CI = 1.25-4.05] for 6-7 comorbidities; and HR = 2.91 [95% CI = 1.54-5.50] for 8-16 comorbidities). Participants with 8-16 comorbidities had a higher total burden of ICD therapy (adjusted relative risk [RR] = 2.12 [95% CI = 1.43-3.16]), a higher burden of inappropriate therapy (RR = 3.39 [95% CI = 1.67-6.86]), and a higher risk of receiving inappropriate vs appropriate therapy (RR = 1.74 [95% CI = 1.07-2.82]). Comorbidity burden was not significantly associated with receipt of appropriate ICD therapies. Patterns were similar when separately examining shock or ATP therapies.
CONCLUSIONS: In primary prevention ICD recipients, MCC burden was independently associated with an increased risk of inappropriate but not appropriate device therapies. Comorbidity burden should be considered when engaging patients in shared decision making about ICD implantation.
© 2019 The American Geriatrics Society.

Entities:  

Keywords:  chronic disease; comorbidity; implantable cardioverter-defibrillator; multimorbidity; patient-centered outcomes

Mesh:

Year:  2019        PMID: 30892695      PMCID: PMC6743319          DOI: 10.1111/jgs.15839

Source DB:  PubMed          Journal:  J Am Geriatr Soc        ISSN: 0002-8614            Impact factor:   5.562


  38 in total

1.  Medicare coverage of ICDs.

Authors:  Mark B McClellan; Sean R Tunis
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

2.  Partnerships in translation: advancing research and clinical care. The 14th Annual HMO Research Network Conference, April 13-16, 2008, Minneapolis, Minnesota.

Authors:  Robert T Greenlee; Laura A Coleman; Andrew F Nelson; Joseph V Selby
Journal:  Clin Med Res       Date:  2008-12

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure.

Authors:  Gust H Bardy; Kerry L Lee; Daniel B Mark; Jeanne E Poole; Douglas L Packer; Robin Boineau; Michael Domanski; Charles Troutman; Jill Anderson; George Johnson; Steven E McNulty; Nancy Clapp-Channing; Linda D Davidson-Ray; Elizabeth S Fraulo; Daniel P Fishbein; Richard M Luceri; John H Ip
Journal:  N Engl J Med       Date:  2005-01-20       Impact factor: 91.245

5.  Risk factors for appropriate cardioverter-defibrillator shocks, inappropriate cardioverter-defibrillator shocks, and time to mortality in 549 patients with heart failure.

Authors:  Harit Desai; Wilbert S Aronow; Chul Ahn; Kaushang Gandhi; Sadaf Hussain; Hoang M Lai; Mala Sharma; William H Frishman; Martin Cohen; Carmine Sorbera
Journal:  Am J Cardiol       Date:  2010-03-11       Impact factor: 2.778

6.  Frequency and causes of implantable cardioverter-defibrillator therapies: is device therapy proarrhythmic?

Authors:  Joseph J Germano; Matthew Reynolds; Vidal Essebag; Mark E Josephson
Journal:  Am J Cardiol       Date:  2006-03-09       Impact factor: 2.778

7.  Quality of life with defibrillator therapy or amiodarone in heart failure.

Authors:  Daniel B Mark; Kevin J Anstrom; Jie L Sun; Nancy E Clapp-Channing; Anastasios A Tsiatis; Linda Davidson-Ray; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

8.  Prognostic importance of defibrillator shocks in patients with heart failure.

Authors:  Jeanne E Poole; George W Johnson; Anne S Hellkamp; Jill Anderson; David J Callans; Merritt H Raitt; Ramakota K Reddy; Francis E Marchlinski; Raymond Yee; Thomas Guarnieri; Mario Talajic; David J Wilber; Daniel P Fishbein; Douglas L Packer; Daniel B Mark; Kerry L Lee; Gust H Bardy
Journal:  N Engl J Med       Date:  2008-09-04       Impact factor: 91.245

9.  Prevalence and prognostic impact of comorbidities in heart failure patients with implantable cardioverter defibrillator.

Authors:  Christian Bruch; Chahrebanu Bruch; Jürgen Sindermann; Günter Breithardt; Rainer Gradaus
Journal:  Europace       Date:  2007-05-16       Impact factor: 5.214

10.  The Cardiovascular Research Network: a new paradigm for cardiovascular quality and outcomes research.

Authors:  Alan S Go; David J Magid; Barbara Wells; Sue Hee Sung; Andrea E Cassidy-Bushrow; Robert T Greenlee; Robert D Langer; Tracy A Lieu; Karen L Margolis; Frederick A Masoudi; Catherine J McNeal; Glen H Murata; Katherine M Newton; Rachel Novotny; Kristi Reynolds; Douglas W Roblin; David H Smith; Suma Vupputuri; Robert E White; Jean Olson; John S Rumsfeld; Jerry H Gurwitz
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2008-11
View more
  1 in total

1.  Progression of infarct-mediated arrhythmogenesis in a rodent model of heart failure.

Authors:  Ikeotunye Royal Chinyere; Talal Moukabary; Mathew D Hutchinson; Jordan J Lancaster; Elizabeth Juneman; Steven Goldman
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-11-08       Impact factor: 4.733

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.